Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

Recent & Breaking News (NDAQ:LEXX)

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

GlobeNewswire August 4, 2021

The StockTalk Cannabis Report: July 30, 2021

Dave Jackson July 30, 2021

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

TheNewsWire July 29, 2021

DehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7,000 Stores

TheNewsWire July 28, 2021

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

Accesswire July 28, 2021

Lexaria Bioscience receives US$3.8M from warrant exercises

Stockhouse Editorial July 27, 2021

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

TheNewsWire July 27, 2021

Lexaria Receives US$3,817,643 From Warrant Exercises

TheNewsWire July 26, 2021

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Accesswire July 22, 2021

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Accesswire July 21, 2021

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council

TheNewsWire July 15, 2021

Lexaria Receives Patent Protection in Japan

TheNewsWire July 13, 2021

The StockTalk Cannabis Report: July 9, 2021

Dave Jackson July 9, 2021

CSE Bulletin: Delist - Lexaria Bioscience Corp. (LXX)

Newsfile July 8, 2021

Lexaria announces voluntary delisting from CSE to concentrate trading on Nasdaq

Stockhouse Editorial July 6, 2021

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

Accesswire July 5, 2021

Lexaria Announces 2021 Annual Meeting Results

Accesswire June 29, 2021

COVID-19 Study Could Greatly Enhance Opportunities to Treat Viral Infections

Jonathon Brown June 21, 2021

Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021

GlobeNewswire June 21, 2021

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

TheNewsWire June 15, 2021